EDIT Logo

Editas Medicine, Inc. (EDIT) 

NASDAQ
Market Cap
$186.64M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
224 of 966
Rank in Industry
137 of 554

Largest Insider Buys in Sector

EDIT Stock Price History Chart

EDIT Stock Performance

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Insider Activity of Editas Medicine, Inc.

Over the last 12 months, insiders at Editas Medicine, Inc. have bought $253,868 and sold $1.23M worth of Editas Medicine, Inc. stock.

On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $837,319 and sold $1.27M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hopfield Jessica (director) — $1.02M.

The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.

List of Insider Buy and Sell Transactions, Editas Medicine, Inc.

2024-12-03SaleCEO
1,618
0.0021%
$2.08$3,361+0.51%
2024-12-03SaleEVP, CHIEF MEDICAL OFFICER
541
0.0007%
$2.08$1,124+0.51%
2024-09-04SaleCEO
1,555
0.0018%
$3.42$5,325-8.57%
2024-09-04SaleEVP, CHIEF MEDICAL OFFICER
518
0.0006%
$3.42$1,774-8.57%
2024-07-25SaleEVP, CHIEF SCIENTIFIC OFFICER
11,886
0.0141%
$5.42$64,370-38.78%
2024-07-19SaleEVP, CHIEF MEDICAL OFFICER
6,619
0.0084%
$5.21$34,456-31.00%
2024-06-04SaleCEO
12,191
0.0142%
$5.50$66,997-35.22%
2024-06-04SaleEVP, CHIEF MEDICAL OFFICER
511
0.0006%
$5.50$2,808-35.22%
2024-05-20SaleEVP, CHIEF FINANCIAL OFFICER
22,337
0.0276%
$5.61$125,404-31.52%
2024-05-13Purchasedirector
45,000
0.0541%
$5.64$253,868-32.92%
2024-03-05SaleCEO
77,824
0.0981%
$9.42$732,884-44.47%
2024-03-04SaleSVP, CHIEF MEDICAL OFFICER
20,327
0.0237%
$9.42$191,425-48.79%
2023-12-05SaleEVP, CBO AND CTO
103
0.0001%
$10.90$1,122-49.09%
2023-11-14SaleEVP, CBO AND CTO
695
0.0008%
$8.21$5,706-32.59%
2023-11-07SaleEVP, CBO AND CTO
139
0.0002%
$8.40$1,168-33.46%
2023-09-06SaleEVP, CBO AND CTO
103
0.0001%
$8.82$908-21.66%
2023-08-11SaleEVP, CBO AND CTO
702
0.0009%
$8.59$6,033-14.46%
2023-08-08SaleEVP, CBO AND CTO
141
0.0002%
$8.39$1,183-16.18%
2023-07-19SaleSVP, CHIEF MEDICAL OFFICER
4,317
0.0062%
$8.80$37,990-10.49%
2023-06-05SaleCEO
6,486
0.0095%
$9.50$61,638-12.82%

Insider Historical Profitability

12.72%
O'Neill Gilmore NeilCEO
312106
0.3781%
$2.2605
Mei BaisongEVP, CHIEF MEDICAL OFFICER
133354
0.1615%
$2.2606
Lucera ErickEVP, CHIEF FINANCIAL OFFICER
116829
0.1415%
$2.2601
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
73136
0.0886%
$2.2601
Hopfield Jessicadirector
67700
0.082%
$2.2640<0.0001%
Polaris Venture Management Co. VI, L.L.C.10 percent owner
3797144
4.5999%
$2.2609
Bitterman Kevindirector
2797144
3.3885%
$2.26010
VIKING GLOBAL INVESTORS LP
2729808
3.3069%
$2.2610
VIKING GLOBAL PERFORMANCE LLC
2729808
3.3069%
$2.2610
Bosley KatrinePresident and CEO
1204966
1.4597%
$2.26026
Flynn James E10 percent owner
954700
1.1565%
$2.2610+20.25%
Glucksmann AlexandraChief Operating Officer
117788
0.1427%
$2.2603
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICER
106610
0.1291%
$2.26012
MULLEN JAMES CCEO
75898
0.0919%
$2.2622<0.0001%
Eaton BruceEVP, CBO AND CTO
74791
0.0906%
$2.26023
Shearman Mark SEVP, CHIEF SCIENTIFIC OFFICER
65559
0.0794%
$2.2602
Collins CynthiaCEO
43760
0.053%
$2.2603
Nikolic Borisdirector
35000
0.0424%
$2.2610+77.16%
Albright CharlesEVP/Chief Scientific Officer
24907
0.0302%
$2.26014
Michaels Lisa AnneEVP/Chief Medical Officer
18432
0.0223%
$2.2601
Cox Gerald FrankChief Medical Officer
4000
0.0048%
$2.2610+77.16%
STARR KEVIN P10 percent owner
0
0%
$2.2601
Hack Andrew A. F.Chief Financial Officer
0
0%
$2.26021
Myer VickeshChief Technology Officer
0
0%
$2.26018

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
State Street$65M10.658.76M+72.8%+$27.38M<0.01
The Vanguard Group$63.48M10.48.56M+1.11%+$695,550.80<0.01
BlackRock$58.12M9.537.83M-0.08%-$45,914.96<0.01
Deep Track Capital Lp$41.01M6.725.53M+0.99%+$402,193.680.19
Dimensional Fund Advisors$19.35M3.172.61M+9%+$1.6M0.01
Millennium Management LLC$16.6M2.722.24M+40.6%+$4.79M0.01
Geode Capital Management$14.43M2.371.94M+2.26%+$319,308.72<0.01
Morgan Stanley$13.24M2.171.78M+41.06%+$3.85M<0.01
Goldman Sachs$10.39M1.71.4M+152.84%+$6.28M<0.01
Two Sigma$10.3M1.691.39M-4.76%-$515,037.020.02
Two Sigma Advisers LP$9.16M1.51.23M+8.13%+$688,576.000.02
D. E. Shaw & Co.$8.08M1.321.09M-8.28%-$729,564.100.01
Qube Research & Technologies$7.76M1.271.05M+172.6%+$4.91M0.01
Nuveen$7.59M1.241.02M+58.44%+$2.8M<0.01
JPMorgan Chase$7.28M1.19981,521-6.61%-$515,586.13<0.01
Credit Suisse$6.7M1.1903,257+0.76%+$50,315.020.01
Squarepoint Ops LLC$6.67M1.09898,456+54.43%+$2.35M0.02
Renaissance Technologies$6.67M1.09898,418+77.06%+$2.9M0.01
Bank of America$6.65M1.09896,647+140.98%+$3.89M<0.01
Woodline Partners LP$6.64M1.09895,000-0.04%-$2,975.420.06
Charles Schwab$6.35M1.04856,095+25.16%+$1.28M<0.01
Rafferty Asset Management Llc$6.33M1.04853,114+108.55%+$3.29M0.02
Northern Trust$6.18M1.01832,880-4.26%-$275,192.98<0.01
Marshall Wace$5.87M0.96791,320-28.79%-$2.37M0.01
Citadel Advisors LLC$5.31M0.87715,917-20.51%-$1.37M<0.01
Citigroup$5.13M0.84691,933+361%+$4.02M<0.01
UBS$4.42M0.73595,965+313.84%+$3.35M<0.01
Integral Health Asset Management Llc$3.34M0.55450,000New+$3.34M0.34
Raymond James Associates$2.61M0.43351,822+35.81%+$688,301.40<0.01
Mirae Asset Global Investments Co Ltd$2.25M0.38314,774+59%+$833,549.53<0.01
Balyasny Asset Management Llc$2.17M0.36292,710+393.42%+$1.73M0.01
BNY Mellon$2.11M0.35284,822-9.08%-$211,024.68<0.0001
Neuberger Berman$2.04M0.33275,069New+$2.04M<0.01
State Of Michigan Retirement System$2.03M0.33273,7210%+$00.01
Stifel$1.73M0.28233,703+53.13%+$601,688.06<0.01
Susquehanna International Group$1.56M0.26210,348+208.32%+$1.05M<0.01
Trexquant Investment LP$1.48M0.24199,205-17.6%-$315,713.560.03
Connor Clark & Lunn Investment Management Ltd$1.3M0.21175,555+1,104%+$1.19M<0.01
Jane Street Capital$1.22M0.2164,874-0.82%-$10,113.46<0.01
Los Angeles Capital Management LLC$1.1M0.18147,883New+$1.1M<0.01
Swiss National Bank$1.07M0.18144,8000%+$0<0.01
Barclays$1.07M0.18144,723-48.21%-$999,722.48<0.0001
RhumbLine Advisers$995,188.000.16134,124+2.08%+$20,315.71<0.01
Kennedy Capital Management Inc$988,448.000.16133,214New+$988,448.000.02
Wells Fargo$956,079.000.16128,852+10.58%+$91,473.49<0.0001
Profund Advisors Llc$918,900.000.15123,841+112.91%+$487,300.960.02
Jacobs Levy Equity Management$884,019.000.15119,140-58.17%-$1.23M<0.01
American Century Investments$824,748.000.14111,152+35.45%+$215,877.52<0.01
JENNISON ASSOCIATES LLC$790,379.000.13106,520+29.08%+$178,080.14<0.01
Man Group Plc$755,111.000.12101,767+32.79%+$186,471.98<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.